



**ASX and Media Release
21 December 2012**

Viralytics Share Purchase Plan raises \$3.5 Million

Viralytics Limited (ASX: VLA) is pleased to advise that its 2012 Share Purchase Plan ("SPP") was again strongly supported by shareholders.

The Company raised \$3.5M under the SPP, further strengthening the Company's cash position. The Company has exercised its discretion to accept oversubscriptions above the target of \$3M, in accordance with the ASX Listing Rules.

The funds raised by the SPP will be used primarily for working capital to provide for the Company's intravenous cancer trial, for continuation of clinical research and development of CAVATAK™.

The funds raised by the SPP exceeded the underwritten amount of \$2M and so there will be no shortfall shares issued to the underwriter.

Shares subscribed for by shareholders will be allotted on 24 December 2012 and are expected to commence trading on the ASX on 28 December 2012.

The Board thanks shareholders for their ongoing support of the Company.

For further information contact:

Paul Hopper
Executive Chairman
Viralytics Limited
T: + 1 858 334 5820 or + 1 310 393 6632
E: receptogen@earthlink.net

Website: www.viralytics.com

About Viralytics Ltd: Viralytics is listed on the Australian Securities Exchange (ASX code: VLA), Viralytics ADR trades under VRACY on the OTC market in the USA. Viralytics' principal asset is the intellectual property relating to CAVATAK™, an Oncolytic Virus technology. CAVATAK™ is the trade name for Viralytics' proprietary formulation of the Coxsackievirus Type A21 (CVA21). EVATAK™ is the trade name for Viralytics' proprietary formulation of the Echovirus Type 1 (EV1). CVA21 and EV1 are viruses that occur naturally in the community. CVA21 and EV1 attach to the outside of cells using a specific 'receptor' on the cell's surface (like a key fitting a lock). CVA21 uses the receptors, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF) to bind and infect target cells. Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types including: melanoma, prostate cancer, breast cancer and multiple myeloma. EV1 uses the receptor integrin α2β1 (alpha 2 beta 1) to bind and infect target cells. Integrin α2β1 (alpha 2 beta 1) has been demonstrated to be highly expressed on multiple cancer types, including: prostate cancer, ovarian cancer.